[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342917-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342917-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-immunotoxin-targeting-prlr-increases-tamoxifen-sensitivity-and-enhances-the-efficacy-of-chemotherapy-in-breast-cancer","The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer","","Tamoxifen can treat ERα-positive breast cancer, yet acquired tamoxifen resistance remains a major clinical barrier. This study examines how activating the prolactin receptor (PRLR) pathway may synergize with ERα signaling to promote progression and whether PRLR-axis targeting improves tamoxifen response. Analyses of TCGA, Metabric, and GEO RNA-seq data, cell models, and PRL-driven PRLR activation were combined with construction of N8-PE24 to test drug sensitivity in vitro and in vivo.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-immunotoxin-targeting-prlr-increases-tamoxifen-sensitivity-and-enhances-the-efficacy-of-chemotherapy-in-breast-cancer/342917/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-immunotoxin-targeting-prlr-increases-tamoxifen-sensitivity-and-enhances-the-efficacy-of-chemotherapy-in-breast-cancer/342917.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is tamoxifen resistance a key issue in ERα-positive breast cancer?","Question",{"text":63,"@type":64},"Although tamoxifen is effective initially, resistance commonly develops during clinical treatment. The study focuses on mechanisms that contribute to reduced tamoxifen sensitivity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does PRL-PRLR signaling play in tamoxifen response?",{"text":68,"@type":64},"PRL-activated PRLR signaling was shown to decrease sensitivity of ERα-positive breast cancer cells to tamoxifen. Tamoxifen treatment also increased PRLR transcription and protein accumulation in a way linked to lysosome alkalization.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the PRLR-targeting immunotoxin N8-PE24 affect therapy outcomes?",{"text":72,"@type":64},"N8-PE24 enhanced tamoxifen sensitivity in vitro and in vivo. In xenograft models, it significantly improved the efficacy of tamoxifen and paclitaxel in PRLR-positive triple-negative breast cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342917,1790452343,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Zhang et al. Journal of Experimental & Clinical Cancer Research (2024) 43:173 [https://doi.org/10.1186/s13046-024-03099-4](https://doi.org/10.1186/s13046-024-03099-4)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nThe immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer  \nJiawei Zhang 1, Junjun Liu 1, Yali Yue 1, Lei Wang 1, Qunye He 1, Shuyi Xu 1, Junyan Li 1, Yunji Liao 1, Yu Chen 1, Shusheng Wang2, Yueqing Xie2,3, Baohong Zhang 1, Yanlin Bian 1, Dimiter S. Dimitrov4, Yunsheng Yuan 1* and Jianwei Zhu 1,2,3*  \nAbstract  \nBackground Though tamoxifen achieves success in treating estrogen receptor α (ERα)-positive breast cancer, the followed development of tamoxifen resistance is a common challenge in clinic. Signals downstream of prolactin receptor (PRLR) could synergize with ERα in breast cancer progression. However, the potential effect of targeting PRLPRLR axis combined with tamoxifen has not been thoroughly investigated.  \nMethods High-throughput RNA-seq data obtained from TCGA, Metabric and GEO datasets were analyzed to explore PRLR expression in breast cancer cell and the association of PRLR expression with tamoxifen treatment. Exogenous or PRL overexpression cell models were employed to investigate the role of activated PRLR pathway in mediating tamoxifen insensitivity. Immunotoxin targeting PRLR (N8-PE24) was constructed with splicing-intein technique, and the efficacy of N8-PE24 against breast cancer was evaluated using in vitro and in vivo methods, including analysis of cells growth or apoptosis, 3D spheroids culture, and animal xenografts.  \nResults PRLR pathway activated by PRL could significantly decrease sensitivity of ERα-positive breast cancer cells to tamoxifen. Tamoxifen treatment upregulated transcription of PRLR and could induce significant accumulation of PRLR protein in breast cancer cells by alkalizing lysosomes. Meanwhile, tamoxifen-resistant MCF7 achieved by longterm tamoxifen pressure exhibited both upregulated transcription and protein level of PRLR. Immunotoxin N8-PE24 enhanced sensitivity of breast cancer cells to tamoxifen both in vitro and in vivo. In xenograft models, N8-PE24 significantly enhanced the efficacy of tamoxifen and paclitaxel when treating PRLR-positive triple-negative breast cancer.  \nConclusions PRL-PRLR axis potentially associates with tamoxifen insensitivity in ERα-positive breast cancer cells. N8-PE24 could inhibit cell growth of the breast cancers and promote drug sensitivity of PRLR-positive breast cancer cells to tamoxifen and paclitaxel. Our study provides a new perspective for targeting PRLR to treat breast cancer.  \n*Correspondence: Yunsheng Yuan [Yunsheng@sjtu.edu.cn](Yunsheng@sjtu.edu.cn)[ ](Yunsheng@sjtu.edu.cn)Jianwei Zhu [jianweiz@sjtu.edu.cn](jianweiz@sjtu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero","cbCaivSuSG714B0Y","https://ap.wps.com/l/cbCaivSuSG714B0Y","pdf",6464913,18,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Highlights\n# Introduction","[{\"question\":\"Why is tamoxifen resistance a key issue in ERα-positive breast cancer?\",\"answer\":\"Although tamoxifen is effective initially, resistance commonly develops during clinical treatment. The study focuses on mechanisms that contribute to reduced tamoxifen sensitivity.\"},{\"question\":\"What role does PRL-PRLR signaling play in tamoxifen response?\",\"answer\":\"PRL-activated PRLR signaling was shown to decrease sensitivity of ERα-positive breast cancer cells to tamoxifen. Tamoxifen treatment also increased PRLR transcription and protein accumulation in a way linked to lysosome alkalization.\"},{\"question\":\"How does the PRLR-targeting immunotoxin N8-PE24 affect therapy outcomes?\",\"answer\":\"N8-PE24 enhanced tamoxifen sensitivity in vitro and in vivo. In xenograft models, it significantly improved the efficacy of tamoxifen and paclitaxel in PRLR-positive triple-negative breast cancer.\"}]","The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer | PDF",1790048850,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96a7a7a00b1201506f91d85b2c36b70f.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/503c2bb186c996a124f0704040024ddf.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0225ca67ed6b7e01967421db59d4f897.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7efbbd6a4a42686e51dff2148dbbd66.webp",980,1306]